Altogether, these imply that C5EOSEW5050ESA may confer gemcitabine-resistant pancreatic cancer cells to necrotic cell death through the blockade of the Notch signalling pathway by downregulating Notch1 ICD, HES-1, and HEY-2 to potentiate gemcitabine sensitivity in resistant pancreatic cancer cells. This evidence concerns the gene HES1 and pancreatic neoplasm.